Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term progression-free survival. Found 9 abstracts

Fakhry C, Zhang Q, Gillison ML, Nguyen-Tan PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM, Barrett WL, Thorstad WL, Yom SS, Wong SJ, Ridge JA, Rao SS, Spencer S, Fortin A, Raben D, Harris J, Le QT. Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials. Cancer. 2019 Jun 15;125(12):2027-38.   PMCID: PMC6594017
Hayashi N, Nakamura S, Tokuda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Serum HER2 levels determined by two methods in patients with metastatic breast cancer. International Journal of Clinical Oncology. 2012 Feb;17(1):55-62.   PMCID: *
LaCasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012 Mar;119(9):2093-9.   PMCID: not NIH funded
Smith MR, Li HL, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A, Kahl BS, Advani R, Hong FX, Horning SJ. Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90-Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. Journal of Clinical Oncology. 2012 Sep;30(25):3119-26.   PMCID: PMC 3732008
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Naganuma M, Dwyer MA. Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Dec;10(12):1487-98.   PMCID: Not NIH fund
Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. Journal of Clinical Oncology. 2011 Mar;29(7):934-43.   PMCID: PMC3068065
Maradeo ME, Cairns P. Translational application of epigenetic alterations: Ovarian cancer as a model. Febs Letters. 2011 Jul;585(13):2112-20.   PMCID: PMC3129436
Zorn KK, Tian CQ, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK. The Prognostic Value of Pretreatment CA 125 in Patients With Advanced Ovarian Carcinoma A Gynecologic Oncology Group Study. Cancer. 2009 Mar;115(5):1028-35.   PMCID: PMC 2664510
Morris GJ, Millenson MM, Padavic-Shaller K, Wang H, Rogatko A, Clyde J, Boyd RL, Yeslow G, Halbherr T, Schilder RJ, Smith MR. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphorna. Haematologica. 2004 Dec;89(12):1484-91.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term progression-free survival

progression-free survival multicenter chronic lymphocytic-leukemia head and neck cancer pancreatic endocrine tumors rituximab MicroRNA octreotide lar international prognostic index Radiation Therapy Oncology Group (RTOG) term-follow-up maintenance rituximab allelic alterations maintenance therapy final analysis Metastasis stem-like cells nucleotide polymorphism analysis chemoimmunotherapy INTRAPERITONEAL CISPLATIN overall survival PHASE-III TRIAL immunochemotherapy phase-ii trial radioimmunotherapy sporadic breast chop multiple-myeloma transplantation maintenance human papillomavirus (HPV) sponsored-working-group microrna expression profiles grading system CA-125 c-erbb-2 protein overexpression Group patients human breast-cancer prospective randomized-trial PACLITAXEL Serum HER2 epithelial ovarian cancer european mcl network therapeutic deescalation clinical utility chemotherapy dna methylation neu her-2 somatostatin analog study-group tumor burden Breast neoplasm superior cooperative-oncology-group prospective phase-ii ANTIGEN MONOCLONAL-ANTIBODY region CARBOPLATIN extracellular domain follicular lymphoma prognostic-factors sites initial therapy 1987 arlson me-journal of chronic diseases-v40-p373 randomized-trial tumor-suppressor gene oncoprotein expression mantle-cell lymphoma Translational research trastuzumab-based therapy Histone modification risk stratification follow-up Trastuzumab cpg-island hypermethylation STAGE-III bendamustine Methylation HER2 covalent histone modifications therapeutic deintensification Gynecologic Oncology tumor wisconsin-oncology-network alpha-interferon fludarabine-low-grade NHL recursive partititioning analysis advanced follicular lymphoma CA 125 tumor marker brca1 promoter CANCER previously untreated mipi glsg Ovarian cancer metastatic carcinoid-tumors oropharyngeal cancer
Last updated on Monday, August 10, 2020